Lamotrigine Treatment of Refractory Bipolar Disorder
J Clin Psychiatry 1997;58(6):271-273 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Lamotrigine represents a new class of anticonvulsant
for the treatment of adult patients with refractory partial seizures.
Lamotrigine is chemically unrelated to carbamazepine
and phenytoin, but is thought to act at voltage-sensitive sodium
channels to stabilize neuronal membranes and inhibit transmitter
release, principally glutamate and aspartate, similar to the
inhibition of neuronal activity produced by phenytoin and carbamazepine.
Further, lamotrigine has been shown to possess
efficacy similar to that of carbamazepine in control of onset of
partial seizures and primary generalized tonic-clonic seizures.